Internal Google data shows that requests to the Gemini API more than doubled between March and August 2025, indicating a sharp uptick in enterprise adoption. According to a report by The Information, this surge has translated into significant incremental revenue for Google Cloud’s server and infrastructure business. Industry sources estimate that API-based model access now accounts for roughly 15% of Google Cloud’s total sales growth, up from 8% a year ago. As customers layer on complementary software solutions—designed to run atop Gemini and improve margins—Google expects AI-driven revenue to contribute over $10 billion to its top line in fiscal 2026, representing a year-over-year increase of more than 50%.

In his annual letter, YouTube CEO Neal Mohan—reporting to Alphabet’s executive suite—outlined enhancements to combat low-quality AI-generated videos, or “AI slop.” The platform now flags deepfakes using its expanded “likeness detection” system, rolled out to over 2 million creators in the YouTube Partner Program. Mohan noted that more than 1 million channels used YouTube’s AI creation tools daily in December 2025. By integrating these safeguards and requiring creator disclosure on altered content, Alphabet aims to preserve advertiser and user trust, safeguarding a revenue stream that has contributed over $30 billion annually to Google Services.

Isomorphic Labs, Alphabet’s AI-driven drug discovery subsidiary, announced that its first clinical trials are now expected by the end of 2026, a delay from its prior mid-2026 guidance. CEO Demis Hassabis attributed the shift to extended preclinical validation efforts for its lead oncology candidate, which has demonstrated subnanomolar potency in vitro. Alphabet has committed $1.5 billion in additional R&D funding to support Isomorphic’s expanded pipeline, which now includes four programs in areas such as neurodegeneration and metabolic disease. Investors monitoring Alphabet’s innovation spend will view this timeline adjustment as a near-term headwind to the company’s long-term biopharma aspirations.